================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: January 22, 2004
QLT Inc.
------------------------------------------------------
(Exact name of registrant as specified in its Charter)
British Columbia, Canada 000-17082 N/A
- ------------------------ ------------------------ -------------------
(Jurisdiction of (Commission File Number) (IRS Employer
Incorporation) Identification No.)
QLT Inc.,
887 Great Northern Way,
Vancouver, B.C., CANADA, V5T 4T5
(604) 707-7000
----------------------------------------------------
(Address, including zip code, and telephone number,
including area code, of principal executive offices)
================================================================================
ITEM 5. OTHER EVENTS
On January 22, 2004, QLT Inc. reported that its alliance partner,
Novartis, announced global Visudyne(R) (verteporfin) sales of
approximately US$95.9 million for the quarter and US$357 million for
the year ended December 31, 2003. This represents an increase of 24%
over sales in the fourth quarter of 2002 and 24% over annual sales in
2002.
ITEM 7. EXHIBITS
Exhibit
Number Description
- ------- -----------
99.1 Press release dated January 22, 2004
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
QLT Inc.
------------
(Registrant)
Date January 22, 2004 /s/ Paul J. Hastings
---------------- -------------------------------------
(Signature)
President and Chief Executive Officer